Soricimed is a private company with multiple oncology programs in clinical and preclinical development. To date, we have been financed by high-net-worth individuals and angel investors. We are now seeking to raise additional funds to advance our multiple programs as they each approach near-term inflection points.
If you are an Accredited Investor and are interested in learning more about investment opportunities with Soricimed Biopharma, please contact us.
We have developed a novel and proprietary TRPV6-targeting peptide platform enabling highly targeted treatments for several solid tumor cancers
Multiple TRPV6 applications in clinical and preclinical development approaching near-term inflection points
We are further along as it relates to utilizing TRPV6 as a target than anyone else in oncology
FDA orphan drug status has been obtained for SOR-C13 for the treatment of pancreatic and ovarian cancers